I would suggest this pertains to using dermal matrices over more traditional surgical methods and not relating to synthetic vs non-synthetic costs debate. We already know this product is significantly cheaper than biologicals, I think they want larger multi-centre trials investigating cost-benefit ratios regarding synthetic use vs traditional methods which is commonplace for adopting a new product as status quo.
I would suggest this pertains to using dermal matrices over more...
-
- There are more pages in this discussion • 2,351 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.54 |
Change
0.120(4.96%) |
Mkt cap ! $1.754B | |||
| Open | High | Low | Value | Volume |
| $2.50 | $2.54 | $2.43 | $4.835M | 1.931M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 81780 | $2.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.54 | 5610 | 4 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |